Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is showing promising data in early patient studies. Recent examination suggests that https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/